Human BCC sensitivity to AP-1 inhibitors ex vivo correlates with nMRTF status and surface marker expression, providing pre-clinical support for AP-1 inhibition as a viable target for combination therapy along with canonical SMO inhibition for resistant BCCs. Here, FOS is linked to skin basal cell carcinoma.